First Time Loading...
G

GemPharmatech Co Ltd
SSE:688046

Watchlist Manager
GemPharmatech Co Ltd
SSE:688046
Watchlist
Price: 12.72 CNY -2.45% Market Closed
Updated: May 5, 2024
Section:
 

Wall Street
Price Targets

Price Targets Summary
GemPharmatech Co Ltd

Wall Street analysts forecast GemPharmatech Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GemPharmatech Co Ltd is 23.26 CNY with a low forecast of 16.8 CNY and a high forecast of 28.11 CNY.

Lowest Forecast
Wall Street Target
16.8 CNY
32% Upside
Average Forecast
Wall Street Target
23.26 CNY
83% Upside
Highest Forecast
Wall Street Target
28.11 CNY
121% Upside
Lowest
Price Target
16.8 CNY
32% Upside
Average
Price Target
23.26 CNY
83% Upside
Highest
Price Target
28.11 CNY
121% Upside
GemPharmatech Co Ltd Competitors:
Price Targets
O
ORPH
Open Orphan PLC
199% Upside
TMO
Thermo Fisher Scientific Inc
10% Upside
SFZN
Siegfried Holding AG
19% Upside
TECH
Bio-Techne Corp
6% Upside
O
ORPH
Open Orphan PLC
199% Upside
TMO
Thermo Fisher Scientific Inc
10% Upside
SFZN
Siegfried Holding AG
19% Upside
TECH
Bio-Techne Corp
6% Upside
PIQ
Proteomics International Laboratories Ltd
34% Upside
688621
Beijing Sun-Novo Pharmaceutical Research Co Ltd
33% Upside
300347
Hangzhou Tigermed Consulting Co Ltd
31% Upside
688315
Novogene Co Ltd
63% Upside

Revenue
Forecast

Revenue Estimate
GemPharmatech Co Ltd

For the last 3 years the compound annual growth rate for GemPharmatech Co Ltd's revenue is 39%. The projected CAGR for the next 3 years is 28%.

39%
Past Growth
28%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
GemPharmatech Co Ltd

For the last 3 years the compound annual growth rate for GemPharmatech Co Ltd's operating income is 55%. The projected CAGR for the next 3 years is 19%.

55%
Past Growth
19%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
GemPharmatech Co Ltd

For the last 3 years the compound annual growth rate for GemPharmatech Co Ltd's net income is 68%. The projected CAGR for the next 3 years is 22%.

68%
Past Growth
22%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is GemPharmatech Co Ltd's stock price target?
Price Target
23.26 CNY

According to Wall Street analysts, the average 1-year price target for GemPharmatech Co Ltd is 23.26 CNY with a low forecast of 16.8 CNY and a high forecast of 28.11 CNY.

What is GemPharmatech Co Ltd's Revenue forecast?
Projected CAGR
28%

For the last 3 years the compound annual growth rate for GemPharmatech Co Ltd's revenue is 39%. The projected CAGR for the next 3 years is 28%.

What is GemPharmatech Co Ltd's Operating Income forecast?
Projected CAGR
19%

For the last 3 years the compound annual growth rate for GemPharmatech Co Ltd's operating income is 55%. The projected CAGR for the next 3 years is 19%.

What is GemPharmatech Co Ltd's Net Income forecast?
Projected CAGR
22%

For the last 3 years the compound annual growth rate for GemPharmatech Co Ltd's net income is 68%. The projected CAGR for the next 3 years is 22%.

ALPHA SPREAD
Join more than 134,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.